Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Mind Medicine Mindmed Inc (MNMD)

Mind Medicine Mindmed Inc (MNMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Trump Signs Psychedelics Order to Speed Ibogaine Research, Opening New Path for PTSD Treatment Quiver Quantitative, Inc. - Sat Apr 18, 7:34PM CDT

President Donald Trump signed an executive order on April 18 directing the FDA to accelerate review pathways for psychedelic-based treatments including ibogaine, while committing $50 million to related...

CMPS : 9.31 (-3.52%)
MNMD : 15.02 (+1.01%)
A concept image of a woman placing a psychedelic pill in her open mouth by BLACKDAY via Shutterstock_com
Wall Street Thinks This 1 Psychedelic Stock Can Gain 335% in 2026 Barchart - Thu Dec 25, 2025

As mental health treatment evolves, MindMed’s advancing psychedelic pipeline and strong 2025 rally have Jones Trading penciling in gains that could more than quadruple the stock from here.

MNMD : 15.02 (+1.01%)
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire - Thu Dec 18, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 15.02 (+1.01%)
MindMed Announces New Employee Inducement Grant Business Wire - Mon Dec 15, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 15.02 (+1.01%)
MindMed Announces New Employee Inducement Grants Business Wire - Mon Dec 1, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 15.02 (+1.01%)
MindMed Reports Q3 2025 Financial Results and Business Updates Business Wire - Thu Nov 6, 2025

-- Anticipated topline data readouts on track for ongoing Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD: Voyage (1H 2026) and Panorama (2H 2026)-- ...

MNMD : 15.02 (+1.01%)
MindMed to Participate in Upcoming Investor Conferences Business Wire - Wed Nov 5, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 15.02 (+1.01%)
MindMed Announces New Employee Inducement Grant Business Wire - Mon Nov 3, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 15.02 (+1.01%)
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares Business Wire - Mon Nov 3, 2025

Mind Medicine (MindMed) Inc . (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders,...

MNMD : 15.02 (+1.01%)
MindMed to Report Q3 2025 Financial Results on November 6, 2025 Business Wire - Thu Oct 30, 2025

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today...

MNMD : 15.02 (+1.01%)

Barchart Exclusives

Why SanDisk’s Wild 462% Rally Has Wall Street Divided Barchart - 11 minutes ago
Wall Street is split on whether SanDisk is building a long-term AI powerhouse or heading toward a painful correction. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.